Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe optimal initial treatment strategies for CML
- Discuss the role of higher imatinib doses in the management of high-risk chronic-phase CML
- Describe appropriate management of a patient with chronic-phase CML in cytogenetic relapse following initial response to treatment with imatinib
Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.